Lifecore Biomedical, Inc. Common Stock (LFCR) is a publicly traded Healthcare sector company. As of May 21, 2026, LFCR trades at $4.57 with a market cap of $164.29M and a P/E ratio of -3.53. LFCR moved +4.34% today. Year to date, LFCR is -41.41%; over the trailing twelve months it is -31.07%. Its 52-week range spans $3.63 to $8.98. Analyst consensus is strong buy with an average price target of $6.67. Rallies surfaces LFCR's financials, insider trades, hedge fund holdings, congressional trades, analyst ratings, and AI-generated research below.
Lifecore Biomedical Q1 Revenue Falls 34% to $23.2M, Reaffirms $120M-$125M Guidance: Lifecore Biomedical posted Q1 revenues of $23.2 million, down 34% year-over-year, with gross margin falling to 19% and a net loss of $15.0 million (-$0.43 per share). The company signed three new commercial site transfer programs and reaffirmed full-year revenue guidance of $120-125 million and adjusted EBITDA of $20.5-25 million.
| Metric | Value |
|---|---|
| Price | $4.57 |
| Market Cap | $164.29M |
| P/E Ratio | -3.53 |
| EPS | $-1.27 |
| Dividend Yield | 0.00% |
| 52-Week High | $8.98 |
| 52-Week Low | $3.63 |
| Volume | 0 |
| Avg Volume | 0 |
| Revenue (TTM) | $128.87M |
| Net Income | $-38.72M |
| Gross Margin | 31.27% |
4 analysts cover LFCR: 0 strong buy, 3 buy, 1 hold, 0 sell, 0 strong sell. Consensus rating is strong buy. Average price target: $6.67.